Preconception and Pregnancy Obesity Treatment and Prevention Among Women With a History of Depression

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT03053323
Collaborator
(none)
24
1
1
69.4
0.3

Study Details

Study Description

Brief Summary

The purpose of the Preconception and Pregnancy Obesity Treatment and Prevention Among Women with A History of Depression preliminary study is to provide a lifestyle intervention for women with a history of depression who are trying to conceive or are pregnant in order to prevent excessive pre-pregnancy weights, avoid excessive gestational weight gain, and to improve other markers of metabolic health. The treatment program consists of 10 private sessions with a trained clinician at no cost to participants.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Lifestyle Intervention
N/A

Detailed Description

The investigators are evaluating a new lifestyle intervention to help women with a history of depression who are pregnant or trying to conceive to learn to exercise, eat well, and live a healthy lifestyle. They are interested in examining if this therapy-based program can positively impact eating and exercising habits and see if the treatment is enjoyable. All participants will receive this intervention.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
24 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Preconception and Pregnancy Obesity Treatment and Prevention Among Women With a History of Depression
Actual Study Start Date :
Feb 17, 2017
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Lifestyle Intervention

Behavioral: Lifestyle Intervention
The lifestyle intervention consists of three components: nutrition, physical activity, and other areas of wellness. The intervention is administered individually each week for 10 weeks and is tailored for women with a history of depression who are in the first trimester of pregnancy or trying to conceive.

Outcome Measures

Primary Outcome Measures

  1. Feasibility of treatment measured by participation rates [10 weeks]

    Participation rates measure attendance at weekly sessions.

  2. Acceptability of treatment on Client Satisfaction Questionnaire (CSQ-8) [10 weeks]

    The CSQ-8 is a reliable and valid self-report measure of satisfaction with care and perceived quality and acceptability of treatment.

Secondary Outcome Measures

  1. Weight loss [10 weeks]

    Weight will be measured during pre-, mid-, and post-treatment visits.

  2. Exercise duration on the Exercise Questionnaire (EQ) [10 weeks]

    The EQ assesses baseline exercise history and ongoing exercise duration and frequency.

  3. Depression severity on the Montgomery-Asberg Depression Rating Scale (MADRS) [10 weeks]

    The MADRS assesses the presence and severity of patient's current depressive symptoms.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • History of depression

  • Pregnant in first trimester or planning to become pregnant within next year

  • Ability to give informed consent

  • Age > or = 18 and < 45 years

  • Overweight or obese (Body mass index > 25 kg/m^2)

Exclusion Criteria:
  • Unwilling/unable to comply with study procedures

  • Endorsed item on the Physical Activity Readiness Questionnaire (PAR-Q)

  • Diagnosis of anorexia nervosa or bulimia nervosa in the past month

  • Diagnosis of substance dependence in the past month

  • Active suicidality (Montgomery Asberg Depression Rating Scale (MADRS) item 10 score >

  • Exercising regularly (i.e., 5 days per week for 30 min)

  • Neurologic disorder or history of head trauma

  • Contraindications to exercise or diet interventions (e.g., co-morbid nutritional and metabolic diseases, physical injuries, contraindications to exercise for pregnant women)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Massachusetts General Hospital Boston Massachusetts United States 02114

Sponsors and Collaborators

  • Massachusetts General Hospital

Investigators

  • Principal Investigator: Louisa Sylvia, PhD, Massachusetts General Hospital
  • Principal Investigator: Marlene Freeman, MD, Massachusetts General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Louisa Grandin Sylvia, Director of Psychology, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT03053323
Other Study ID Numbers:
  • 2016P002556
First Posted:
Feb 15, 2017
Last Update Posted:
Feb 20, 2020
Last Verified:
Feb 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Louisa Grandin Sylvia, Director of Psychology, Massachusetts General Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 20, 2020